--- title: "Olympus Scope Lawsuit: Duodenoscope, CRE Superbug, and MAJ-891 Recall Litigation Guide for Attorneys" url: https://www.masstortmarketingagency.com/blogs/olympus-scope-lawsuit canonical: https://www.masstortmarketingagency.com/blogs/olympus-scope-lawsuit published: 2026-04-23 modified: 2026-04-23 author: name: Tarun role: Founder, Mass Tort Agency publisher: name: Mass Tort Agency url: https://www.masstortmarketingagency.com description: | Attorney-facing brief on the Olympus scope litigation: the bacteria-trapping design defect in TJF-Q180V and TJF-160F duodenoscopes, the 400+ infections and 35 deaths confirmed by the Senate HELP Committee, the January 2025 MAJ-891 Class I recall, the June 2025 FDA import alert on 58 products, the $6.6M Bigler verdict and 2018 $85M criminal fine, case values, qualifying criteria, and intake strategy. keywords: - Olympus scope lawsuit - duodenoscope CRE infection - MAJ-891 recall - TJF-Q180V - Bigler verdict - medical device litigation 2026 license: | Cite freely with attribution to Mass Tort Agency. Verbatim quoting permitted with citation back to the canonical URL. --- # Olympus Scope Lawsuit: Duodenoscope, CRE Superbug, and MAJ-891 Recall Litigation Guide for Attorneys > **Quick answer.** The U.S. Senate HELP Committee confirmed more than 400 > infections tied to contaminated Olympus duodenoscopes across 36+ hospitals > with at least 35 deaths. Internal documents show Olympus identified the > defect in 2012, warned European hospitals in 2013–2014, and did not notify > U.S. hospitals until February 2015; in 2018 Olympus paid an $85 million > criminal fine. The January 2025 Class I recall of the MAJ-891 tubing set > (120 injuries, 1 death), the June 2025 FDA import alert on 58 products, > the October 2025 Urgent Field Safety Notice, and the March 2026 Health > Canada recall have expanded the litigation. The Bigler verdict — $6.6 > million plus $250,000 in concealment sanctions — is the reference point on > case value. ## Why Olympus scope litigation is the most attorney-friendly tort of 2026 Every mass tort lives on three questions: is there a confirmed defect, is there strong evidence the defendant knew, and is there a large identifiable population of injured patients? Olympus scope litigation answers all three. The Senate HELP Committee's 2016 report confirmed **more than 400 infections** across 36+ U.S. hospitals with **at least 35 deaths** — and that was the baseline before the January 2025 MAJ-891 recall (120 additional injuries, 1 death), the June 2025 FDA import alert on 58 Olympus products, the October 2025 Urgent Field Safety Notice (2 additional deaths, 5 injuries), and the March 2026 Health Canada recall. The knowledge evidence is arguably the strongest in any active product liability litigation: internal communications produced in *Bigler v. Olympus* show the company identified the bacteria-trapping defect in the TJF-Q180V duodenoscope as early as **2012**, warned European hospitals in 2013 and 2014, and delayed notifying U.S. hospitals until **February 2015**. In 2018, Olympus Medical Systems Corp. paid an **$85 million criminal fine** and pleaded guilty to failing to report device-related injuries to the FDA. ## The defect: why Olympus scopes trap bacteria after cleaning Duodenoscopes are flexible, side-viewing endoscopes used in ERCP (Endoscopic Retrograde Cholangiopancreatography) to access the bile and pancreatic ducts. The Olympus TJF-Q180V and TJF-160F designs have an **elevator mechanism** at the distal tip with tight crevices and sealed channels that standard reprocessing cycles cannot fully penetrate. Bacterial biofilm — especially carbapenem-resistant Enterobacteriaceae (**CRE**) — survives cleaning and transmits patient to patient even when hospitals follow the manufacturer's reprocessing instructions perfectly. The FDA confirmed that Olympus's own instructions, followed correctly, did not fully decontaminate the device — the backbone of the design defect claims. CRE is classified by the CDC as an "urgent threat" antibiotic-resistant organism; invasive CRE infections carry a mortality rate of roughly **50%**. Survivors often spend weeks in the ICU, undergo multiple surgeries, and carry permanent organ damage — the damages profile behind the $6.6 million Bigler verdict and the additional $250,000 concealment sanction. ## The MAJ-891 recall and why it broadened the litigation In January 2025, Olympus issued a Class I recall of the **MAJ-891 single-use tubing set** used with its endoscope irrigation pumps, after **120 reports of injuries and 1 death** linked to tubing failures that could contaminate the patient or procedure field. The recall matters strategically for three reasons: - **It expanded the device universe** — claims now reach cystoscopy, ureteroscopy, choledochoscopy, and hysteroscopy patients, not just ERCP patients. - **It added a second liability theory** — manufacturing defect and failure-to-warn tied to a specific Class I recall, alongside the original design defect claims. - **It reset the statute of limitations for many claimants** — patients whose scope procedure was years ago may have fresh claims if a MAJ-891 tubing failure was involved. The June 2025 FDA import alert on 58 Olympus products and the October 2025 Urgent Field Safety Notice reinforced the pattern: this is no longer a single-device litigation. ## Government and regulatory record - **2012** — Virginia Mason Medical Center (Seattle) reports a CRE outbreak linked to Olympus duodenoscopes; Olympus engineers internally confirm the defect. - **2013–2014** — Olympus warns European hospitals; U.S. hospitals are not notified. - **February 2015** — Olympus issues its U.S. safety communication, three years after internal identification. - **2016** — Senate HELP Committee report: 400+ infections at 36+ hospitals, at least 35 deaths. - **2018** — Olympus pleads guilty and pays an $85 million criminal fine for failing to report device injuries to the FDA. - **January 2025** — Class I recall of MAJ-891 tubing sets (120 injuries, 1 death). - **June 2025** — FDA import alert on 58 Olympus products. - **October 2025** — Urgent Field Safety Notice: 2 additional deaths, 5 injuries. - **March 2026** — Health Canada recall. Almost every element of notice, concealment, and continuing harm is in the public record via federal agencies and a Senate committee — lowering discovery costs and weakening motions to dismiss. ## The defendant: can Olympus pay? Yes. Olympus Corp. has **$6.75 billion** in annual consolidated revenue, a market capitalization around **$13.5 billion**, and roughly **85%** of the U.S. duodenoscope market. It has an established history of paying: the 2018 $85 million fine and the Bigler $6.6 million verdict plus $250,000 sanctions were both paid. Olympus is solvent, cash-flowing, and publicly traded — the inverse of bankruptcy-shadowed emerging torts. ## Qualifying criteria: who is a claimant **Required:** - A procedure using an Olympus duodenoscope (TJF-Q180V, TJF-160F), cystoscope, ureteroscope, choledochoscope, or hysteroscope — or involving the MAJ-891 tubing set — at a U.S. hospital or ambulatory surgical center from **2012 onward**. - A bacterial infection diagnosed within approximately **30 days** of the procedure: CRE, sepsis, bacteremia, E. coli, Klebsiella, Pseudomonas, cholangitis, or post-procedure urinary tract infection. - Infection requiring **hospitalization, ICU admission, or extended medical treatment** (outpatient antibiotics with quick full recovery is generally not viable). **Strongly preferred:** hospital records confirming the Olympus device (scope serial number, procedure note, reprocessing log); culture results identifying the organism, especially CRE; evidence of permanent injury or wrongful death. **Exclusions:** clear alternative causation; claims outside the applicable statute of limitations with no discovery rule argument; claimants already represented for the same claim. ## Case value framework - **Tier 1 — Wrongful death or catastrophic outcome:** seven-figure range; the Bigler case ($6.6M verdict plus $250K concealment sanctions) is the reference point. - **Tier 2 — Severe CRE or sepsis with ICU admission:** high six figures. - **Tier 3 — Hospitalized infection with recovery:** mid six figures. - **Tier 4 — Documented lower-severity infection:** low six figures or below; best held for aggregated resolution. Economic damages run high because CRE treatment is expensive and prolonged; non-economic damages benefit from the concealment narrative. ## Statute of limitations and the discovery rule Most states apply a **2 to 4 year** limitations period from the date of injury or the date the claimant reasonably should have discovered the device link. The discovery rule matters here because the defect was not disclosed to U.S. hospitals until February 2015, many patients were told their infections were generic hospital-acquired infections, and the MAJ-891 recall was not announced until January 2025. Wrongful death limitations generally run from the date of death. ## How to build Olympus scope intake Intake must confirm both the procedure record and the infection record — typically held by different providers. The flow: (1) procedure confirmation — ERCP, cystoscopy, ureteroscopy, choledochoscopy, or hysteroscopy at a U.S. facility from 2012 onward, capturing facility, date, and procedure type; (2) infection confirmation — bacterial infection, sepsis, CRE, or bloodstream infection within ~30 days, with hospitalization/ICU status; (3) documentation collection — operative notes, reprocessing logs, culture results, discharge summaries, with HIPAA authorizations; (4) conflict and duplicate check; (5) retainer execution via e-signature on the initial call — deferring execution loses meaningful conversion. Firms without a standing [mass tort intake operation](https://www.masstortmarketingagency.com/blogs/mass-tort-intake-guide) should not learn on this tort — the medical complexity rewards experienced intake teams or tort-trained outsourced partners. ## Marketing and lead acquisition strategy The qualifying population is smaller and more clinically specific than broad consumer torts like [hair relaxer](https://www.masstortmarketingagency.com/mass-tort-leads/hair-relaxer) or [Roundup](https://www.masstortmarketingagency.com/mass-tort-leads/roundup). Effective channels: high-intent targeted search ("duodenoscope infection," "CRE after ERCP," "Olympus scope lawsuit"); medical record retrieval partnerships; CRE survivor and sepsis support group outreach; infectious disease and gastroenterology referrals; and TV/broad digital only with tight screening. Cost per qualified lead runs higher than broad consumer torts but settles more reliably. Lead program: https://www.masstortmarketingagency.com/mass-tort-leads/olympus-scope. ## What to do in the next 30 days 1. Ethical review and conflict check in every state you plan to solicit. 2. Intake criteria freeze — everyone screens to the same approved criteria. 3. Records retrieval capacity — internal or outsourced, across multiple health systems. 4. Marketing launch — targeted search and support group outreach first; TV only after intake conversion stabilizes. 5. Lead partner — exclusive, with Olympus-specific screening; non-exclusive partners burn spend on duplicates. ## Frequently asked questions ### What is the Olympus scope lawsuit? Product liability litigation against Olympus Corporation and its U.S. subsidiary alleging its duodenoscopes, cystoscopes, ureteroscopes, choledochoscopes, and hysteroscopes have a design defect that traps bacteria after cleaning, causing CRE superbug infections, sepsis, and other life-threatening illnesses. The Senate HELP Committee confirmed 400+ infections across 36+ hospitals and at least 35 deaths; claims expanded after the January 2025 MAJ-891 recall, the June 2025 FDA import alert on 58 products, and the October 2025 Urgent Field Safety Notice. ### Which Olympus scope models are involved? The core devices are the TJF-Q180V and TJF-160F duodenoscopes used in ERCP. The recalled MAJ-891 tubing set is central to current claims, and litigation is expanding to other Olympus flexible endoscopes with similar reprocessing flaws. Olympus controls roughly 85% of the U.S. duodenoscope market. ### Who qualifies as a claimant? A patient who underwent an Olympus scope procedure (typically ERCP, cystoscopy, ureteroscopy, or related) at a U.S. facility from 2012 onward and was diagnosed with a bacterial infection, sepsis, or CRE within approximately 30 days, with documented hospitalization, ICU admission, or prolonged antibiotic treatment. Wrongful death claims are accepted where the decedent died of post-procedure infection complications. ### What are the typical injuries? CRE infection is the signature injury (~50% mortality in invasive cases); also sepsis and septic shock, bacteremia, E. coli, Klebsiella, and Pseudomonas infections, cholangitis and post-ERCP infections, and UTIs after cystoscopy or ureteroscopy. Many patients spent weeks in the ICU, required multiple surgeries, and carry permanent organ damage. ### What is the MAJ-891 recall? A January 2025 Class I recall of the MAJ-891 single-use tubing set used with Olympus endoscope irrigation pumps, after 120 reported injuries and one death. The FDA cited a risk that tubing failure could contaminate patients or procedure fields. It triggered a second wave of claims and broadened the litigation beyond the duodenoscope defect theory. ### What is the case value? The Bigler verdict delivered $6.6 million to a single plaintiff plus $250,000 in sanctions against Olympus for concealment. Bellwether planning suggests high six figures on average for serious CRE or sepsis cases with hospitalization, and seven figures for wrongful death or catastrophic outcomes. Lower-severity values are still being established. ### What evidence does Olympus have liability? Internal communications show Olympus engineers identified the defect as early as 2012 (after Virginia Mason outbreak reports), warned European hospitals in 2013–2014, and delayed U.S. notification until February 2015. In 2018, Olympus's U.S. subsidiary paid an $85 million criminal fine and pleaded guilty to failing to report device injuries to the FDA. The 2025 recall, FDA import alert, and March 2026 Health Canada recall add fresh regulatory findings. ### What is the statute of limitations? Typically 2 to 4 years by state, from injury or from when the claimant reasonably should have known the infection was device-linked. Discovery rules favor patients because the defect was not publicly known to most patients until 2015 at the earliest, and the MAJ-891 recall did not occur until 2025. Wrongful death claims generally run from the date of death. ## The bottom line for mass tort firms A confirmed defect backed by federal findings, unusually strong concealment evidence, and a solvent defendant — with the MAJ-891 recall, FDA import alert, and Urgent Field Safety Notice broadening the claimant universe faster than most firms have responded. The Bigler verdict is the floor on what these cases can be worth with the right facts.